Imperial College London

ProfessorEricAboagye

Faculty of MedicineDepartment of Surgery & Cancer

Professor
 
 
 
//

Contact

 

+44 (0)20 3313 3759eric.aboagye

 
 
//

Assistant

 

Mrs Maureen Francis +44 (0)20 7594 2793

 
//

Location

 

GN1Commonwealth BuildingHammersmith Campus

//

Summary

 

Publications

Publication Type
Year
to

351 results found

Rosso L, Brock CS, Gallo JM, Saleem A, Price PM, Turkheimer FE, Aboagye EOet al., 2009, Development of a New Pharmacokinetic Model for the Prediction of Temozolomide Disposition in Gliomas Using Positron Emission Tomography Imaging, EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, Vol: 36, Pages: S270-S271, ISSN: 1619-7070

Journal article

Ali S, Heathcote DA, Kroll SHB, Jogalekar AS, Scheiper B, Patel H, Brackow J, Siwicka A, Fuchter MJ, Periyasamy M, Tolhurst RS, Kanneganti SK, Snyder JP, Liotta DC, Aboagye EO, Barrett AGM, Coombes RCet al., 2009, The Development of a Selective Cyclin-Dependent Kinase Inhibitor That Shows Antitumor Activity, CANCER RESEARCH, Vol: 69, Pages: 6208-6215, ISSN: 0008-5472

Journal article

Contractor KB, Aboagye EO, 2009, Monitoring Predominantly Cytostatic Treatment Response with F-18-FDG PET, JOURNAL OF NUCLEAR MEDICINE, Vol: 50, Pages: 97S-105S, ISSN: 0161-5505

Journal article

Chapon C, Jackson JS, Aboagye EO, Herlihy AH, Jones WA, Bhakoo KKet al., 2009, An In Vivo Multimodal Imaging Study Using MRI and PET of Stem Cell Transplantation after Myocardial Infarction in Rats, MOLECULAR IMAGING AND BIOLOGY, Vol: 11, Pages: 31-38, ISSN: 1536-1632

Journal article

Rosso L, Brock CS, Gallo JM, Saleem A, Price PM, Turkheimer FE, Aboagye EOet al., 2009, A New Model for Prediction of Drug Distribution in Tumor and Normal Tissues: Pharmacokinetics of Temozolomide in Glioma Patients, CANCER RESEARCH, Vol: 69, Pages: 120-127, ISSN: 0008-5472

Journal article

Julius Leyton, Graham Smith, Yongjun Zhao, Meg Perumal, Quang-De Nguyen, Edward Robins, Erik Arstad, Eric O Aboagyeet al., 2009, [18F]Fluoromethyl-[1,2-2H4]-Choline: A Novel Radiotracer for Imaging Choline Metabolism in Tumors by Positron Emission Tomography, Cancer Research, Vol: 22, Pages: 7721-7728

Journal article

Smith G, Glaser M, Perumal M, Nguyen Q-D, Shan B, Arstad E, Aboagye EOet al., 2008, Design, Synthesis, and Biological Characterization of a Caspase 3/7 Selective Isatin Labeled with 2-[F-18]fluoroethylazide, JOURNAL OF MEDICINAL CHEMISTRY, Vol: 51, Pages: 8057-8067, ISSN: 0022-2623

Journal article

McParland BJ, Miller MP, Spinks TJ, Kenny LM, Osman S, Khela MK, Aboagye E, Coombes RC, Hui AM, Cohen PSet al., 2008, The biodistribution and radiation dosimetry of the Arg-Gly-Asp peptide 18F-AH111585 in healthy volunteers, Journal of Nuclear Medicine, Vol: 49, Pages: 1664-1667

We report the safety, biodistribution, and internal radiation dosimetry of a new PET tracer, (18)F-AH111585, a peptide with a high affinity for the alpha(v)beta(3) integrin receptor involved in angiogenesis. METHODS: PET scans of 8 healthy volunteers were acquired at time points up to 4 h after a bolus injection of (18)F-AH111585. (18)F activity in whole blood and plasma and excreted urine were measured up to 4 h after injection. In vivo (18)F activities in up to 12 source regions were determined from quantitative analysis of the images. The cumulated activities subsequently calculated were then used to determine the internal radiation dosimetry, including the effective dose. RESULTS: Injection of (18)F-AH111585 was well tolerated in all subjects, with no serious or drug-related adverse events reported. The main route of (18)F excretion was renal (37%), and the 3 highest initial uptakes were by liver (15%); combined walls of the small, upper large, and lower large intestines (11%); and kidneys (9%). The 3 highest absorbed doses were received by the urinary bladder wall (124 microGy/MBq), kidneys (102 microGy/MBq), and cardiac wall (59 microGy/MBq). The effective dose was 26 microGy/MBq. CONCLUSION: (18)F-AH111585 is a safe PET tracer with a dosimetry profile comparable to other common (18)F PET tracers.

Journal article

McParland BJ, Miller MP, Spinks TJ, Kenny LM, Osman S, Khela MK, Aboagye E, Coombes RC, Hui A-M, Cohen PSet al., 2008, The Biodistribution and Radiation Dosimetry of the Arg-Gly-Asp Peptide F-18-AH111585 in Healthy Volunteers, JOURNAL OF NUCLEAR MEDICINE, Vol: 49, Pages: 1664-1667, ISSN: 0161-5505

Journal article

Leyton J, Smith G, Lees M, Perumal M, Nguyen Q-D, Aigbirhio FI, Golovko O, He Q, Workman P, Aboagye EOet al., 2008, Noninvasive imaging of cell proliferation following mitogenic extracellular kinase inhibition by PD0325901, MOLECULAR CANCER THERAPEUTICS, Vol: 7, Pages: 3112-3121, ISSN: 1535-7163

Journal article

Kenny LM, Coombes RC, Oulie I, Contractor KB, Miller M, Spinks TJ, McParland B, Cohen PS, Hui A-M, Palmieri C, Osman S, Glaser M, Turton D, At-Nahhas A, Aboagye EOet al., 2008, Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand F-18-AH111585 in breast cancer patients, JOURNAL OF NUCLEAR MEDICINE, Vol: 49, Pages: 879-886, ISSN: 0161-5505

Journal article

Pillai RG, Forster M, Perumal M, Mitchell F, Leyton J, Aibgirhio FI, Golovko O, Jackman AL, Aboagye EOet al., 2008, Imaging pharmacodynamics of the alpha-folate receptor-targeted thymidylate synthase inhibitor BGC 945, CANCER RESEARCH, Vol: 68, Pages: 3827-3834, ISSN: 0008-5472

Journal article

Saleem A, Aboagye EO, Matthews JC, Price PMet al., 2008, Plasma pharmacokinetic evaluation of cytotoxic agents radiolabelled with positron emitting radioisotopes, CANCER CHEMOTHERAPY AND PHARMACOLOGY, Vol: 61, Pages: 865-873, ISSN: 0344-5704

Journal article

Aboagye EO, 2008, Design and Development of Probes for In vivo Molecular and Functional Imaging of Cancer and Cancer Therapies by Positron Emission Tomography (PET), Modern Biopharmaceuticals: Design, Development and Optimization, Pages: 1243-1270, ISBN: 9783527311842

Molecular imaging with positron emission tomography (PET) is now evolving as a unique non-invasive method for studying tumor and normal tissue biochemistry, physiology, and pharmacology. In oncology, a range of drugs can be radiolabeled for pharmacokinetic studies including "microdosing" of human subjects prior to Phase I trials. Gene delivery can be assessed by incorporating a reporter gene that is detectable by PET within the vector of interest. This chapter also reviews progress made in the PET imaging field in the design of pharmacodynamic markers including assays of cell surface receptor status, angiogenesis, apoptosis, proliferation, glucose metabolism, and hypoxia. Such probes are potentially useful in patient management and for drug development. PET is particularly attractive for the development of cancer-targeted therapies where assessment of plasma drug levels or assays of the target protein in peripheral blood cells are less specific than direct assessment of the tumor or tumor material. The recent introduction of dedicated small-animal scanners has helped bridge in vitro science with in vivo clinical studies for the efficient development of modern biopharmaceuticals. © 2005 WILEY-VCH Verlag GmbH & Co. KGaA.

Book chapter

Aboagye EO, Vigushin DM, 2008, Compounds and uses thereof [HDAC]

Patent

Leyton J, Aboagye EO, 2007, PET Tracers as biomarkers in oncology drug development, MOLECULAR CANCER THERAPEUTICS, Vol: 6, Pages: 3627S-3628S, ISSN: 1535-7163

Journal article

Chan F, Sun C, Perumal M, Nguyen Q-D, Bavetsias V, McDonald E, Martins V, Wilsher NE, Raynaud FI, Valenti M, Eccles S, te Poele R, Workman P, Aboagye EO, Linardopoulos Set al., 2007, Mechanism of action of the Aurora kinase inhibitor CCT129202 and in vivo quantification of biological activity, MOLECULAR CANCER THERAPEUTICS, Vol: 6, Pages: 3147-3157, ISSN: 1535-7163

Journal article

Kenny L, Coombes RC, Vigushin DM, Al-Nahhas A, Shousha S, Aboagye EOet al., 2007, Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3 '-deoxy-3 '-[F-18]fluorothymidine positron emission tomography, EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, Vol: 34, Pages: 1339-1347, ISSN: 1619-7070

Journal article

Aboagye EO, Price PM, Padhani AR, 2006, Imaging of Pharmacodynamic End Points in Clinical Trials, Novel Anticancer Agents, Pages: 299-336, ISBN: 9780120885619

This chapter describes the application of noninvasive imaging methods positron emission tomography (PET) and dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) for the pharmacodynamic evaluation of existing and new cancer therapeutics. PET methodology is being developed to enable evaluation of pathophysiology and pharmacodynamics in oncology. The high sensitivity and specificity of PET assays allow the mechanism of drug action to be assessed in patients. DCE-MRI is one of a number of MRI techniques that evaluates tumors with respect to their state of angiogenesis. There are a number of requirements that need to be met before DCE-MRI techniques can become mainstream diagnostic tools. Requirements include agreed protocols for data acquisition, analysis, and presentation methods. Appropriate imaging processing and visualization tools are needed to achieve this. The image acquisition techniques that are able to sample the whole tumor volume are also needed, particularly if the technique is to be extended to organs with significant physiological motion. It is suggested that macromolecular contrast enhanced MRI may become the preferred choice for these evaluations. © 2006 Elsevier Inc. All rights reserved.

Book chapter

Aboagye EO, 2006, Imaging in drug development., Clin Adv Hematol Oncol, Vol: 4, Pages: 902-904, ISSN: 1543-0790

Journal article

Leyton J, Lockley M, Aerts JL, Baird SK, Aboagye EO, Lemoine NR, McNeish IAet al., 2006, Quantifying the activity of adenoviral E1A CR2 deletion mutants using Renilla luciferase bioluminescence and 3 '-deoxy-3 '-[F-18] fluorothymidine positron emission tomography imaging., CANCER RESEARCH, Vol: 66, Pages: 9178-9185, ISSN: 0008-5472

Journal article

Yau K, Price P, Pillai RG, Aboagye Eet al., 2006, Elevation of radiolabelled thymidine uptake in RIF-1 fibrosarcoma and HT29 colon adenocarcinoma cells after treatment with thymidylate synthase inhibitors, EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, Vol: 33, Pages: 981-987, ISSN: 1619-7070

Journal article

Perumal M, Pillai RG, Barthel H, Leyton J, Latigo JR, Forster M, Mitchell F, Jackman AL, Aboagye EOet al., 2006, Redistribution of nucleoside transporters to the cell membrane provides a novel approach for imaging thymidylate synthase inhibition by positron emission tomography, CANCER RESEARCH, Vol: 66, Pages: 8558-8564, ISSN: 0008-5472

Journal article

Leyton J, Alao JP, Da Costa M, Stavropoulou AV, Latigo JR, Perumal M, Pillai R, He Q, Atadja P, Lam EW-F, Workman P, Vigushin DM, Aboagye EOet al., 2006, In vivo biological activity of the histone deacetylase inhibitor LA0824 is detectable with 3 '-deoxy-3 '-[F-18]fluorothymidine positron emission tomography, CANCER RESEARCH, Vol: 66, Pages: 7621-7629, ISSN: 0008-5472

Journal article

Gupta N, Saleem A, Kotz B, Osman S, Aboagye EO, Phillips R, Vernon C, Wasan H, Jones T, Hoskin PJ, Price PMet al., 2006, Carbogen and nicotinamide increase blood flow and 5-fluorouracil delivery but not 5-fluorouracil retention in colorectal cancer metastases in patients, CLINICAL CANCER RESEARCH, Vol: 12, Pages: 3115-3123, ISSN: 1078-0432

Journal article

Workman P, Aboagye EO, Chung Y-L, Griffiths JR, Hart R, Leach MO, Maxwell RJ, McSheehy PMJ, Price PM, Zweit Jet al., 2006, Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies, JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, Vol: 98, Pages: 580-598, ISSN: 0027-8874

Journal article

Baird SK, Lockley M, Leyton J, Aboagye EO, Lemoine NR, McNeish IAet al., 2006, E1A CR2 deletion mutant adenoviral vectors in ovarian cancer: combination with apoptosis inducers and monitoring with [18F] FLT-PET imaging, Publisher: AMER ASSOC CANCER RESEARCH, ISSN: 0008-5472

Conference paper

Kenny LM, Aboagye EO, Al-Nahhas A, Charles L, Coombes RCet al., 2006, [C-11]choline-PET in human breast cancer: utility, reproducibility and effect of receptor tyrosine kinase inhibition by trastuzumab., 29th Annual San Antonio Breast Cancer Symposium, Publisher: SPRINGER, Pages: S212-S212, ISSN: 0167-6806

Conference paper

Kenny LM, Vigushin DM, Al-Nahhas A, Osman S, Luthra SK, Shousha S, Coombes RC, Aboagye EOet al., 2005, Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by [F-18]fluorothymidine-positron emission tomography imaging: Evaluation of analytical methods., CANCER RESEARCH, Vol: 65, Pages: 10104-10112, ISSN: 0008-5472

Journal article

Leyton J, Latigo JR, Perumal M, Dhaliwal H, He QM, Aboagye EOet al., 2005, Early detection of tumor response to chemotherapy by 3 '-deoxy-3 '-[(18) F]fluorothymidine positron emission tomography: The effect of cisplatin on a fibrosarcoma tumor model in vivo, CANCER RESEARCH, Vol: 65, Pages: 4202-4210, ISSN: 0008-5472

Journal article

This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.

Request URL: http://wlsprd.imperial.ac.uk:80/respub/WEB-INF/jsp/search-html.jsp Request URI: /respub/WEB-INF/jsp/search-html.jsp Query String: id=00169625&limit=30&person=true&page=9&respub-action=search.html